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Abstract 28 
 29 
Background: 30 
Tuberculosis is a major challenge to health in the developing world. Triage prior to 31 
diagnostic testing could potentially reduce the volume of tests and costs associated with 32 
using the more accurate, but costly, Xpert MTB/RIF assay. An effective methodology to 33 
predict the impact of introducing triage prior to tuberculosis diagnostic testing could be 34 
useful in helping to guide policy.  35 
 36 
Methods: 37 
The development and use of operational modelling to project the impact on case 38 
detection and health system costs of alternative triage approaches for tuberculosis, with 39 
or without X-ray, based on data from Porto Alegre City, Brazil. 40 
 41 
Results: 42 
Most of the triage approaches modelled without X-ray were predicted to provide no 43 
significant benefit. One approach based on an artificial neural network applied to patient 44 
and symptom characteristics was projected to increase case detection (82% vs. 75%) 45 
compared to microscopy, and reduce costs compared to Xpert without triage. In addition, 46 
use of X-ray before diagnostic testing for HIV-negative patients could maintain diagnostic 47 
yield of using Xpert without triage, and reduce costs. 48 
 49 
Conclusion: 50 
A model for the impact assessment of alternative triage approaches has been tested. 51 
The results from using the approach demonstrate its usefulness in informing policy in a 52 
typical high burden setting for tuberculosis. 53 
 54 
Key words: Triage, Xpert, X-ray, Model. 55 
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Background 58 
 59 
There were an estimated 1.7 million deaths and 10.4 million new cases of tuberculosis 60 
(TB) in 20161. The standard diagnostic approach for pulmonary-TB relies on sputum 61 
smear microscopy (SSM), but published research shows that SSM has limitations2. 62 
These include accuracy (sensitivity 20-80%)3, the time taken to complete diagnosis and 63 
start treatment (4-20 days)4 and the related costs5-7.  64 
 65 
New diagnostic algorithms to improve accuracy and early diagnosis of TB, including 66 
detection of resistance to TB drugs, are required8. Xpert MTB/RIF (Xpert) is a rapid, 67 
automated molecular test that can detect TB with higher sensitivity (83% to 92%) and, at 68 
the same time, resistance to rifampicin9. However, due to the high cost per test, 69 
implementation of Xpert in many countries is limited5. As an example, Porto Alegre City 70 
in Brazil is a high prevalence setting for TB with high levels of HIV-coinfection10. Data 71 
collected in 2011 as part of the Policy Relevant Outcomes from Validating Evidence on 72 
Impact (PROVE-IT) study in Brazil11 showed the prevalence of TB among presumptive-73 
TB cases at primary health care facilities was 15.8% with HIV coinfection at 44.8%. 74 
Recent research showed 4.7% of smear-positive pulmonary-TB cases were multi-drug 75 
resistant12. Porto Alegre is a city where implementation of Xpert could have a significant 76 
impact on reducing the TB burden. Currently all presumptive-TB cases are diagnostically 77 
tested for TB. If a nurse or clinician could identify using characteristics of the patient and 78 
their symptoms (triage) some of the individuals that do not have TB, then the number of 79 
diagnostic tests conducted could be reduced, saving cost and speeding up access to TB 80 
treatment for those where it is needed13, 14. 81 
 82 
Operational modelling has been used to project health system and patient impacts of 83 
introducing new diagnostic algorithms15-17. Such an approach could be used to evaluate 84 
the impact of triage prior to seeking a diagnosis. This study investigates the use of 85 
operational modelling to predict the impact of seven potential alternative approaches to 86 
triage (including no triage – base case), with or without X-ray and in combination with the 87 
Xpert diagnostic test. The projected outcomes were compared to a base case of sputum 88 
smear microscopy without triage or X-ray prior to diagnostic testing.  89 
 90 
 91 
Methods 92 
 93 
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 94 
 95 
Operational Model 96 
For this study an operational model was chosen as it could be designed to fully represent 97 
the current and potential future patient pathways for diagnosis in Porto Alegre using a 98 
visual and interactive model that could engage decision makers. The activities of triage, 99 
sputum collection, diagnosis, clinical assessment and treatment initiation were modelled. 100 
Waiting areas for patients along with the human resources required for each activity 101 
were represented in the model. A snap shot of the screen layout for the developed model 102 
is shown in Figure 1 including a description of the patient pathways. The model was 103 
developed using the discrete event simulation (DES) package – WITNESS®18. There are 104 
five key elements that need to be defined within any WITNESS® DES model. The first of 105 
these are ‘entities’ representing either people or objects moving around a process. 106 
These entities have ‘attributes’ which can be used to represent either static or changing 107 
features of the entity (e.g. quantity, TB status, patient unique identifier, and time in a 108 
particular process). Entities travel through ‘activities’ (representing processes where time 109 
and resources are involved) and ‘queues’ (representing waiting areas before activities). 110 
Activities can be associated with ‘resources’ such as staff. More detail on the structure of 111 
the model is in the online appendix. The dynamic and visual representation of the 112 
process facilitated validation and calibration of the model.  113 
 114 
Data from January to December 2012 were collated for Porto Alegre City in Brazil, 115 
sourced in part from the PROVE-IT study11 (Table 1) to populate and calibrate the model.  116 
 117 
Triage Tests 118 
Seven potential triage approaches for TB diagnosis were identified using literature 119 
review and expert interviews. These triage approaches were selected on the basis that 120 
they made use of information that would be readily available prior to performing a 121 
diagnostic test. For example, personal data such as age, HIV-status, and tobacco usage, 122 
and clinical symptoms such as cough, fever, chest pain, weight loss, haemoptysis and 123 
other respiratory symptoms22-23. In addition, approaches that could combine this 124 
information to generate a predictive algorithm for active TB were considered24. 125 
Algorithms such as a clinical score25 developed using regression models or an artificial 126 
neural network (ANN)26-27 were identified. For these approaches, some computation 127 
would be necessary by the diagnosing health professional using a scorecard where 128 
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 5 
points are allocated to individual or combinations of characteristics. Six potential 129 
alternative triage approaches with estimated sensitivity and specificity for active 130 
pulmonary-TB were identified (Table 2). For comparison purposes these included the 131 
theoretical target product profiles (TPP) for a triage test proposed by Denkinger et al.28.  132 
 133 
Additional data used in the model is detailed in the online appendix. 134 
 135 
Chest X-ray is also an approach commonly used by programmes for triage. Therefore, 136 
we also considered X-ray in combination with other triage algorithms as a tool to ensure 137 
all patients with X-rays suggestive of TB would receive a diagnostic test 20,29. Therefore, 138 
we modelled an X-ray algorithm as a potential add-on to triage for HIV-negative (or 139 
unknown status) presumptive-TB cases with any abnormality suggestive of active TB. In 140 
these scenarios, it was assumed all HIV-positive presumptive-TB cases would go for 141 
laboratory testing due to the difficulty of detecting TB using X-ray in HIV patients (Figure 142 
2). 143 
 144 
Diagnostic Algorithms 145 
In Porto Alegre two alternative diagnostic algorithms were considered for testing of 146 
presumptive TB cases. Presumptive-TB cases were defined as patients who present 147 
with symptoms or signs suggestive of TB at primary health care facilities in Porto Alegre 148 
City30. The first diagnostic algorithm available was sputum smear microscopy based on 149 
two samples collected on different days followed by a clinical assessment for smear 150 
negative cases. The second diagnostic algorithm was based on a single sputum sample 151 
tested using Xpert MTB/RIF followed by clinical assessment for Xpert negative cases. 152 
Both these algorithms were modelled. 153 
 154 
Model Outputs 155 
The model projected the impact of introducing each alternative triage approach prior to 156 
the diagnostic test. Note the context here is triage of patients seeking a TB diagnosis 157 
rather than active case finding. The impacts on patients sent for diagnosis, TB cases 158 
identified, false positive diagnoses, time to diagnosis and resource usage were projected 159 
using the model. The case detection rate (defined as the number of patients with active 160 
TB disease that are diagnosed (bacteriologically confirmed or clinically diagnosed) and 161 
start treatment, divided by the number of presumptive TB cases with active TB disease). 162 
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 6 
95% confidence limits were calculated for the key outputs. Sensitivity analysis to the 163 
prevalence of TB in presumptive-TB cases was conducted. 164 
 165 
Costing 166 
A unit cost to the health system was estimated for each test including triage, X-ray and 167 
diagnostic tests (Tables 1 and 2). The unit costs included staff time, consumables, 168 
cartridges, slides, running costs and equipment depreciation. They did not include fixed 169 
overhead costs (e.g. space) as these were assumed unchanged between tests. The 170 
additional cost per triage test was assumed to be low as the characteristics are those 171 
which clinicians will already consider. The X-ray and diagnostic costs were taken from 172 
the Prove-IT study in Brazil11 which used an activity-based approach to take into account 173 
cost drivers relating to physical infrastructure, human resources, supplies (chemicals, 174 
reagents and consumables), and transport. The ratio of the increase in health system 175 
costs divided by the benefits in number of true TB cases starting treatment was also 176 
assessed as a measure to compare alternative triage approaches. 177 
 178 
Results 179 
 180 
Summary projections for the impact of introducing Xpert in Porto Alegre, with or without 181 
triage, for each of the modelled scenarios are shown in Tables 3 (without X-ray) and 4 182 
(with X-ray).  183 
 184 
Without X-ray – Table 3 185 
For the base case of microscopy without triage, the projected volume of individuals 186 
starting TB treatment was 1,238 cases per year (75% case detection rate). This included 187 
bacteriologically confirmed and clinically diagnosed cases and involved 10,281 patients 188 
being tested. The mean time from the patient arriving at the health facility to completing 189 
diagnosis was projected to be 6.0 days. 190 
 191 
Implementation of Xpert without triage was projected to have a significant impact over 192 
the base case. Case detection rate rising to 83% with a projected increase in the number 193 
of people with TB starting treatment of 137 (95% CI. 57, 217) per year and an increase in 194 
the annual diagnostic cost of US$581 thousand (95% CI. 555, 607). The mean cost per 195 
additional TB case treated was projected to be US$4242 (95% CI. 1371, 7111). The 196 
mean time to complete diagnosis was reduced by 1.0 day (5 days compared to 6 days). 197 
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 198 
Implementation of Xpert alongside a triage test of excluding all cases with a cough of 199 
less than one week (T2) gave a projected case detection rate of 72% with a reduction in 200 
the annual number of patients with TB starting treatment of -41 (95% CI. -118, 36) 201 
compared to the base case. Therefore, there would be no benefit of this option over the 202 
current standard diagnostic approach of microscopy. The same was true for 203 
implementation of Xpert alongside a triage test of excluding all cases with a cough less 204 
than three weeks (T3) – case detection rate dropping to 53%. 205 
 206 
Implementation of Xpert together with a triage test using a clinical score (T4) had a 207 
projected reduction in case detection rate to 70% with the annual number of people with 208 
TB starting treatment falling by -90 (95% CI. -166, -14), so despite the lower cost 209 
compared to Xpert without triage, this was not considered a useful intervention. 210 
  211 
Using the predicted sensitivity and specificity of the ANN (T5) as the triage test along 212 
with Xpert as the diagnostic test showed a significant increase in the projected case 213 
detection rate to 82% with an increase in the annual number of TB patients starting 214 
treatment of 131 (95% CI. 39, 223). Projected additional health system costs compared 215 
to the base case were US$367 thousand (95% CI. 351, 384) compared to US$581 216 
thousand (95% CI. 555, 607) for Xpert without triage. This option therefore both 217 
increases case detection compared to the base case and would cost less than roll-out of 218 
Xpert without triage. 219 
 220 
Using a triage test with the performance of the theoretical optimal TPP (T6) with Xpert 221 
was projected to have a positive impact on case detection (80%), cost and time to 222 
complete diagnosis. The projected impact on the annual number of people with TB 223 
starting treatment was an increase of 82 (95% CI. 2, 162) with a significantly reduced 224 
annual health system costs to both microscopy -US$49 thousand (95% CI. -52, -47) and 225 
Xpert without triage.  226 
 227 
Implementation of Xpert alongside a triage test with the minimal TPP characteristics (T7) 228 
was projected to have no significant impact on case detection rate (76%) or the annual 229 
number of TB patients starting treatment compared to microscopy. 230 
 231 
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 8 
Figure 3A illustrates the projections from the model of each scenario with a positive 232 
impact on the number starting treatment compared to the base case. T6 (Optimal TPP) 233 
and T5 (ANN) are the most effective options with reduced cost compared to Xpert 234 
without triage.  235 
 236 
With X-ray – Table 4 237 
These results are based on the same scenarios as those detailed above, but with X-ray 238 
also used as an additional triage tool for HIV-negative (or HIV status unknown) 239 
presumptive-TB cases. For HIV-positive patients these options assume all presumptive-240 
TB cases would receive a TB diagnostic test.  241 
 242 
Implementation of all the triage approaches with X-ray alongside Xpert as the diagnostic 243 
tool would have a significant positive impact on case detection rates compared to the 244 
base case (sputum smear microscopy without triage) i.e. 80-83% compared to 75%. As 245 
shown in Table 4 and Figure 3B the projected increase in the annual number of TB 246 
patients starting treatment for most of the triage approaches matches the increase 247 
projected with no triage when Xpert is the diagnostic tool. The exception is T3 (cough for 248 
greater than three weeks) when the increase is smaller. Comparing the results in Table 3 249 
(without X-ray) with the results in Table 4 (with X-ray) shows annual costs increase due 250 
to X-ray, an increase in the number of diagnostic tests, and additional treatment costs. 251 
However, the projected costs are still below Xpert without triage in all cases. In 252 
particular, T4 (clinical score), T5 (ANN), T6 (TPP- optimal) and T7 (TPP-minimal).  253 
 254 
Sensitivity Analysis  255 
Variation in the outcomes to the sensitivity and specificity parameters of the triage tests 256 
can be seen from the range of different triage tests modelled (i.e. sensitivities ranging 257 
from 61% to 98% and specificities from 19% to 80%). Additional sensitivity analyses to 258 
input parameters such as TB prevalence and costs of tests were also performed. The 259 
results of all the sensitivity analyses are shown in the online appendix. The ranking of 260 
options by effectiveness was unchanged by varying these parameters.  261 
 262 
Discussion 263 
 264 
Operational modelling can provide valuable predictions of the impact on case detection, 265 
health system costs and time to complete diagnosis of alternative triage approaches for 266 
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 9 
TB diagnosis as shown by this study using data from Porto Alegre City, Brazil. The 267 
approach can bring together routine and trial data from the current program along with 268 
data from published and ongoing research to model current and potential future patient 269 
pathways which are critical to understanding patient and health system impacts in 270 
relation to cost and time, as well as yield.  271 
 272 
The WHO strongly recommends Xpert should be used as the initial diagnostic test in 273 
individuals suspected of having TB-HIV coinfection31. In Porto Alegre, Brazil, where TB 274 
and HIV prevalence are high, the rollout of the Xpert test could have a large effect. 275 
However, Xpert is frequently only used as an add-on test to microscopy rather than for 276 
initial diagnosis due to its high cost per test. Our study confirms implementation of Xpert 277 
would provide a significant benefit over microscopy in terms of the number of patients 278 
with TB starting treatment in Porto Alegre City, with case detection rates estimated to 279 
increase from 75% to 83%. Introducing a triage approach prior to the Xpert test could 280 
reduce costs but would also reduce the number of TB patients starting treatment as 281 
some patients that fail the triage test would have TB and would have been identified by 282 
the diagnostic test if they had been tested. For example, a triage test based on cough for 283 
greater than 3 weeks could reduce the number of diagnostic tests by almost half, but 284 
would see many TB cases not being sent for diagnosis leading to case detection falling 285 
to 53%. Most of the triage approaches modelled when combined with Xpert did not 286 
provide any significant benefit over microscopy as the diagnostic test. However, one 287 
triage approach (T5- ANN) was found to significantly increase TB case detection (82% 288 
vs. 75%) compared to microscopy and reduce costs compared to Xpert without triage. 289 
This approach combines patient and symptom data in a score. This is an encouraging 290 
result, but before an ANN approach could be implemented further work is required to 291 
develop the appropriate data collection and computation procedures in the diagnostic 292 
centre. 293 
 294 
The model shows that X-ray combined with a triage approach prior to Xpert diagnostic 295 
testing could deliver almost the same case detection rate as would be achieved when no 296 
triage is used (i.e. 82-83%). This could be achieved at reduced costs compared to using 297 
Xpert for all presumptive-TB cases (i.e. no triage). For example, X-ray combined with the 298 
ANN is projected to reduce costs of the roll-out of Xpert to the TB programme by around 299 
US$130,000 per year in Porto Alegre city. This would require access to X-ray at 300 
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diagnostic facilities, which may not be possible in some locations and would require 301 
further investigation.  302 
 303 
A triage test with the optimal TPP characteristics28 would also be highly effective but is 304 
not available currently. The minimal TPP proposed was not effective as the benefits in 305 
number of TB patients starting treatment would not be increased.  306 
 307 
An additional observation from the modelled diagnostic and triage options is the effect on 308 
reducing false positive diagnoses (i.e. the number of individuals placed on TB treatment 309 
who do not have TB disease). This is an important as the consequences of false 310 
diagnosis for TB can be serious for the individual and the TB programme32. As expected 311 
the use of Xpert as a diagnostic tool compared to microscopy can reduce the rate of 312 
false diagnosis particularly when fewer individuals are clinically diagnosed. Our results 313 
also indicate the use of triage can lead to reduced false positive diagnosis (Tables 3 and 314 
4), especially if the specificity of the triage test is high (e.g. in triage tests T3, T4, T6 and 315 
T7).  316 
 317 
Our study was limited by the availability of some data. Assumptions were necessary from 318 
the literature and interviews with experts, for example in relation to sensitivity of clinical 319 
diagnosis, new triage approaches and associated costs. In addition, it was assumed that 320 
the sensitivity and specificity of each of the tests (i.e. triage, X-ray, sputum smear 321 
microscopy, Xpert and clinical judgement) were conditionally independent. In particular, 322 
this may not be an accurate assumption for triage and clinical judgement as similar 323 
criteria may be used by the nurses and clinicians at triage and following a negative 324 
diagnostic test. However, this would not be expected to affect the levels of true TB 325 
identified through the diagnostic tests. Further analysis of the correlations between tests 326 
would be valuable research. We have not tested the approach in low-HIV or high MDR-327 
TB settings, so further research is required here. The modelling methods used in this 328 
study could also be used to assess impacts on patient costs33 and assessing the impact 329 
of different strategies for active case finding. Active case finding is likely to be essential if 330 
the TB epidemic is to be controlled and is therefore receiving increased focus from the 331 
WHO34 and others35-36.  332 
 333 
Conclusions 334 
 335 
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In conclusion, we have demonstrated that operational modelling as used for this study 336 
can provide insights into the impact of alternative triage approaches. In the context of 337 
Porto Alegre City, we have shown the introduction of a triage approach alongside Xpert 338 
could reduce the TB diagnostic costs of Xpert implementation whilst still significantly 339 
increasing the number of patients starting treatment compared to microscopy. Our study 340 
indicates that among the optional triage approaches modelled - T5 (ANN) has the 341 
greatest potential to improve outcomes whilst controlling costs to the health system. The 342 
optimal TPP28 for TB triage is a theoretical set of performance characteristics for which 343 
no triage tools currently exist, but should it become available would be beneficial. 344 
Furthermore, adding X-ray as a triage tool for HIV-negative cases (and unknown status) 345 
alongside appropriate triage approaches could substantially save costs over Xpert 346 
without triage, whilst identifying almost as many cases.  347 
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Tables 558 
Table 1: Input data  559 
Parameter Value (95% CI) Source 
Mean number of presumptive TB cases per day 44 (34,55) Data collated from 
primary health care 
facilities in Porto 
Alegre for the 
PROVE-IT trial11 
TB prevalence amongst presumptive-TB cases  15.8% (14.6%, 17.0%) 
HIV prevalence in TB cases 44.8% (40.4%, 49.2%) 
HIV prevalence in no TB cases 27.3% (25.8%, 28.8%) 
Sensitivity - Smear microscopy for HIV-positive  45% (38%, 52%) 
Boehme et al19 
Specificity - Smear microscopy for HIV-positive 100% (99%, 100%) 
Sensitivity - Smear microscopy for HIV-negative  72% (69%, 75%) 
Specificity - Smear microscopy for HIV-negative 99% (99%, 100%) 
Sensitivity - Xpert for HIV-positive  82% (77%, 87%) 
Specificity - Xpert for HIV-positive 99% (98%, 100%) 
Sensitivity - Xpert for HIV-negative  92% (90%, 94%) 
Specificity - Xpert for HIV-negative 99% (98%, 99%) 
Sensitivity - Clinical judgement for HIV-positive 
Specificity - Clinical judgement for HIV-positive 
Sensitivity - Clinical judgement for HIV-negative 
Specificity - Clinical judgement for HIV-negative 
49% 
90% 
77% 
90% 
Estimated from 
reported TB case 
volumes in Porto 
Alegre and assumed 
sensitivity/ specificity 
of Smear 
microscopy 
Sensitivity of X-ray for abnormalities suggestive 
of active TB 
87% (79%, 95%) 
WHO20 
Specificity of X-ray for abnormalities suggestive 
of active TB 
89% (87%, 92%) 
Estimated unit cost per test – Microscopy US$7.20 Estimates provided 
by TB research staff 
working with the TB 
program in Porto 
Alegre 
Estimated unit cost per test – Xpert US$ 17.80 
Estimated unit cost per test – X-ray US$ 6.00 
Estimated % of presumptive-TB cases LTFU 10.0% 
Estimated cost to treat TB case in Brazil 
Estimated cost to treat MDR-TB in Brazil 
US$840 
US$6313 
Laurence et al21 
  560 
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Table 2: Optional Triage approaches and key characteristic assumptions 561 
 562 
Triage 
label 
Description of triage 
approach 
Sensitivity Specificity Additional 
cost per 
test+ 
T1- Base 
case 
No triage    
T2- Cough 
1 week 
Respiratory symptom of cough > 
1 week18 
88% 19% US$0 
T3 Cough 
3 weeks 
Respiratory symptom of cough 
>3 weeks18 
61% 51% US$0 
T4- 
Clinical 
Score  
Scorecard based on 
aggregating scores assigned to 
respiratory symptoms including 
chest pain, cough, sputum 
expectoration, hemoptysis, night 
sweats, fever, shortness of 
breath and weight loss18.  
83% 52% US$2 
T5- ANN  Artificial Neural Network (ANN) 
based on using a multilayer 
perceptron (MLP) approach22 to 
infer the probability of a patient 
having active pulmonary-TB 
from personal data and clinical 
symptoms i.e. age, gender, 
cough, fever, weight loss, 
smoker, night sweats, 
hospitalisation, chest pain, 
dyspnea, and hemoptysis.  
98%* 32%* US$2 
T6- TPP 
(optimal) 
A theoretical optimal target 
product profile (TPP) as 
proposed by Denkinger et al.24 
95% 80% US$2 
T7- TPP 
(minimal) 
A theoretical target product 
profile (TPP) with the minimum 
characteristics required to be 
useful as proposed by 
Denkinger et al.24 
90% 70% US$2 
 563 
* - the sensitivity and specificity figures are taken from unpublished research in Brazil 564 
+ - The additional cost per triage test is assumed to be low as the characteristics are those which 565 
clinicians will already consider today. An additional allowance (US$2) has been made if some 566 
computation is required in line with the costs proposed by Denkinger et al23 for the TPP’s.  567 
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Table 3 -  Model projections with Xpert as the diagnostic tool for each triage option when no X-ray available for triage (Figure 1A).  
(Base Case – Microscopy diagnostic tool and no triage) 
 
 Diagnostic              
& Triage 
Options 
Presumptive 
TB cases 
receiving 
diagnostic 
test per yr. 
True TB cases 
b starting 
treatment per 
year and case 
detection % c 
False TB 
cases d 
starting TB 
treatment 
per year 
Time between 
starting triage 
and receiving 
diagnosis 
(days) 
 Additional true 
TB cases 
starting 
treatment over 
base case per 
year a 
Additional cost 
compared to 
base case per 
year a          
(US$ 000s) 
Cost per additional 
true TB patient 
diagnosed and 
treated 
(US$) a 
Microscopy 
No Triage  
(base case) 
10281 
1238 
75% 
543 6.0 0 0 0 
Xpert  
      No Triage  
10284 
1375 
83%  
419 5.0 
137 
(57, 217) 
581 
(555, 607) 
4242 
(1372, 7111) 
Xpert  
T2 Cough 1wk 
8411 
1197 
72% 
340 4.0 
-41 
(-118, 36) 
233 
(223, 244) 
No benefit over 
base 
Xpert  
T3 Cough>3wks  
5183 
878 
53% 
193 2.4 
-360 
(-439, -281) 
-393 
(-410, -375) 
No benefit over 
base 
Xpert  
T4 Clinical score 
5470 
1148 
70% 
191 2.5 
-90 
(-166, -14) 
-51 
(-53, -49) 
No benefit over 
base 
Xpert  
T5     ANN 
7469 
1369 
82% 
285 3.5 
131 
(39, 223) 
367 
(351, 384) 
2805 
(907, 4703) 
Xpert  
T6 TPP optimal   
3290 
1320 
80% 
75 1.5 
82 
(2, 162) 
-49 
(-52, -47) 
-604 
(-1012, -195) 
Xpert  
T7 TPP minimal  
4046 
1245 
76% 
121 1.8 
7 
(-74, 88) 
-54 
(-56, -52) 
Minimal benefit 
over base case 
 
a Numbers in brackets represent 95% confidence limits 
b True TB cases include both bacteriologically confirmed and clinically diagnosed cases that have TB 
c Case detection rate calculated as the number of true TB cases identified through the complete triage and diagnostic algorithm, divided 
by the number of TB cases in the presumptive-TB case population calculated from the assumed TB prevalence (Table 2). 
d False TB cases are individuals diagnosed with TB and placed on TB treatment, but do not have TB (false positives)  
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Table 4 -  Model projections with Xpert as the diagnostic tool for each triage option with X-ray available for triage (Figure 1B). (Base 
Case – Microscopy diagnostic tool and no triage)  
 
 Diagnostic              
& Triage 
Options 
Presumptive 
TB cases 
receiving 
diagnostic test  
per yr. 
True TB cases 
b starting 
treatment per 
year and case 
detection c % 
False TB 
cases d 
starting TB 
treatment 
per year 
Time between 
starting triage 
and receiving 
diagnosis 
(days) 
 Additional true 
TB cases 
starting 
treatment over 
base case per 
year a 
Additional cost 
compared to 
base case per 
year a          
(US$ 000s) 
Cost per 
additional true TB 
patient diagnosed 
and treated 
(US$) a 
Microscopy 
No Triage  
(base case) 
10281 
1238 
75% 
543 6.0 0 0 0 
Xpert  
No Triage 
10284 
1375 
83% 
419 5.0 
137 
(57, 217) 
581 
(555, 607) 
4242 
(1372, 7111) 
Xpert  
T2 Cough 1wk 
9204 
1370 
83% 
401 4.4 
132 
(54, 210) 
536 
(512, 559) 
4057 
(1313, 6802) 
Xpert  
T3 Cough>3wks 
7340 
1290 
80% 
289 3.5 
52 
(-15, 119) 
278 
(266, 290) 
5345 
(1729, 8960) 
Xpert  
T4 Clinical score 
7365 
1353 
82% 
296 3.5 
114 
(38, 190) 
380 
(363, 397) 
3331 
(1078, 5584) 
Xpert  
T5     ANN  
8477 
1352 
82% 
341 4.0 
114 
(43, 187) 
451 
(431, 470) 
3952 
(1278, 6625) 
Xpert  
T6 TPP optimal   
5823 
1354 
82% 
218 2.8 
116 
(45, 187) 
172 
(164, 179) 
1481 
(479, 2483) 
Xpert  
T7 TPP minimal 
6367 
1366 
83% 
231 3.1 
128 
(56, 200) 
301 
(287, 314) 
2349 
(760, 3938) 
 
a Numbers in brackets represent 95% confidence limits 
b TB cases include both bacteriologically confirmed and clinically diagnosed cases that have TB 
c Case detection rate was calculated as the number of true TB cases identified through the complete triage and diagnostic algorithm, 
divided by the number of TB cases in the presumptive-TB case population calculated from the assumed TB prevalence (Table 2). 
d False TB cases are individuals diagnosed with TB and placed on TB treatment, but do not have TB (false positives)   
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Figures Legend 
 
Figure 1 – Example screenshot of operational model of TB diagnostics in Porte 
Alegre 
The screen shot of the model illustrates presumptive-TB cases arriving at 1 of 10 
health clinics where they undergo the triage test followed in some cases by X-ray. 
Patients who are triage positive then proceed for sputum collection. When 
microscopy is used for diagnosis the patients then go home and return the next day 
with a second sputum sample. Sputum samples are tested in the laboratory using 
either microscopy or Xpert MTB/RIF. A red patient icon indicates the patient has 
active TB and a green icon indicates a patient with no TB. Sputum samples and 
results are shown as circles. Circles with brown centres represent initiation of the 
diagnostic test and TB positivity unknown, red and yellow centres indicate samples 
that tested positive and negative respectively. Patients who are tested positive, 
undertake initiation of TB treatment and those who are tested negative go for clinical 
assessment and then TB treatment if clinically diagnosed. Some patients are also 
shown as lost to follow up (LTFU) and no treatment is initiated. Three types of 
resources are also shown in the model to represent Clinicians (Orange and Black), 
Nurses (Pink and Yellow) and Lab Assistants (Green and Brown). 
 
Figure 2 – Alternative presumptive-TB algorithms for triage and X-ray prior to TB 
diagnostic testing 
 
Figure 3 –Projections on the impacts of implementing alternative triage approaches 
(T2-T7) 
Impacts shown are on health system costs (X-axis), additional cost per additional TB 
patient starting treatment (Y-axis) and number of additional TB patients starting 
treatment (size of circle). Graph A is impact of triage without X-ray. Graph B is impact 
of triage with X-ray. 
 
Additional files 
The following information is contained in the additional file: 
Name - Online appendix – Jan 2019.docx 
Title of data – Input data 
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Description of data – additional input parameters to the developed model that are not 
already shown in Tables 1 and 2 in the main manuscript. Namely 
- Turnaround time distribution observed in the laboratory of Porto Alegre  
- Triage time assumptions in minutes 
- Sputum Collection time distribution reported in Porto Alegre 
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Figure Click here to access/download;Figure;Figure 1 - Model snapshot - Dec 2018.tif
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